文献
J-GLOBAL ID:200902220864724088
整理番号:09A0075980
EGFRおよびErbB-2阻害剤としてのピロリジニルアセチレン性チエノ[3,2-d]ピリミジン類の合成的および立体選択的効果
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors
著者 (22件):
STEVENS Kirk L.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
ALLIGOOD Krystal J.
(Dep. of Oncology Biology, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
ALBERTI Jennifer G. Badiang
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
CAFERRO Thomas R.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
CHAMBERLAIN Stanley D.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
DICKERSON Scott H.
(Dep. of Computational and Structural Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
DICKSON Hamilton D.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
EMERSON Holly K.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
GRIFFIN Robert J.
(Dep. of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
HUBBARD Robert D.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
KEITH Barry R.
(Dep. of Oncology Biology, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
MULLIN Robert J.
(Dep. of Oncology Biology, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
PETROV Kimberly G.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
GERDING Roseanne M.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
RENO Michael J.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
RHEAULT Tara R.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
RUSNAK David W.
(Dep. of Oncology Biology, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
SAMMOND Douglas M.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
SMITH Stephon C.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
UEHLING David E.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
WATERSON Alex G.
(Dep. of Oncology Medicinal Chemistry, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
,
WOOD Edgar R.
(Dep. of Biochemical and Cellular Targets, GlaxoSmithKline, Res. Triangle Park, NC 27709, USA)
資料名:
Bioorganic & Medicinal Chemistry Letters
(Bioorganic & Medicinal Chemistry Letters)
巻:
19
号:
1
ページ:
21-26
発行年:
2009年01月01日
JST資料番号:
W0248A
ISSN:
0960-894X
資料種別:
逐次刊行物 (A)
発行国:
オランダ (NLD)
言語:
英語 (EN)